The aim of this study was to detail the first ESG procedure performed in Brazil, and to evaluate technical feasibility, reproducibility and short-term results as primary therapy for primary obesity treatment. Endoscopic sleeve gastroplasty (ESG) using the endoscopic suture system OverStitch® (Apollo Endosurgery, Austin, Texas, USA) aims to reduce gastric lumen by means of its tubulization, mimicking sleeve gastrectomy surgery and gastric plication. The successful use of ESG using OverStitch® (Apollo Endosurgery, Austin, TX, USA) has been reported in the literature. The device was used to perform plications along the greater curvature of the stomach, creating a tubulization similar to a sleeve gastrectomy. The procedure was successfully performed in 50 minutes, time without bleeding or other complications. The patient presented mild abdominal pain and good acceptance of liquid diet. The endoscopic gastroplasty procedure was safe, with acceptable technical viability, short in duration and without early complications.

The successful use of Endoscopic Sleeve Gastroplasty using OverStitch® (Apollo Endosurgery, Austin, Texas, USA) has been reported in the literature. The device was used to perform plications along the greater curvature of the stomach, creating a tubulization similar to a sleeve gastrectomy. The procedure was successfully performed in 50 minutes, time without bleeding or other complications. The patient presented mild abdominal pain and good acceptance of liquid diet. The endoscopic gastroplasty procedure was safe, with acceptable technical viability, short in duration and without early complications.

ABSTRACT - Background: Less invasive and complex procedures have been developed to treat obesity. The successful use of Endoscopic Sleeve Gastroplasty using OverStitch® (Apollo Endosurgery, Austin, Texas, USA) has been reported in the literature. Aim: Present technical details of the procedure and its surgical/ endoscopic preliminary outcome. Method: The device was used to perform plications along the greater curvature of the stomach, creating a tubulization similar to a sleeve gastrectomy. Result: A male patient with a BMI of 35.17 kg/m² underwent the procedure, with successful achievement of four plications, and preservation of gastric fundus. The procedure was successfully performed in 50 minutes, time without bleeding or other complications. The patient presented mild abdominal pain and good acceptance of liquid diet. Conclusions: The endoscopic gastroplasty procedure was safe, with acceptable technical viability, short in duration and without early complications.

INTRODUCTION

Bariatric surgery is a well-established procedure in cases of body mass index (BMI) >40 kg/m² or in cases of BMI>35 kg/m² with comorbidities. Currently, gastric bypass and sleeve gastrectomy are two of the most used techniques. Endoscopic methods have become increasingly important in the fight against obesity. However, in cases of grade I and II obesity without comorbidities, the best treatment technique is still uncertain.

Despite the positive impact of bariatric surgery, only 1% of possible candidates undergo the procedure due to its high cost, limited access, patient preference and related risks. Due to this low rate of performed surgeries and the reduced efficiency of behavioral methods and clinical treatments, less invasive, complex, and lower cost procedures have been developed in order to reach a larger number of patients.

Endoscopic sleeve gastroplasty (ESG) using the endoscopic suture system OverStitch® (Apollo Endosurgery, Austin, TX, USA) aims to reduce gastric lumen by means of its tubulization, mimicking sleeve gastrectomy surgery and gastric plication, having recently been approved for use in Brazil.

The aim of this study was to detail the first ESG procedure performed in Brazil, evaluating technical feasibility, reproducibility and short-term results as primary endoscopic treatment for non-morbid obesity.

ABCD Arq Bras Cir Dig 2016;29(Supl.1):95-97
METHODS

The study protocol for use of suturing devices (Overstitch®; Apollo Endosurgery, Austin, TX, USA) was approved by the institution’s Ethics Committee (Hospital Associação Portuguesa de Beneficência, SP, Brazil, CAAE 1.603.661). The pilot procedure was performed at the Mário Covas State Hospital, ABC School of Medicine, São Paulo, Brazil, following signature of a consent form.

Technique

The procedure was performed in an operating room under general anesthesia with orotracheal intubation. The patient was placed in left lateral decubitus, with administration of prophylactic antibiotics (ciprofloxacin). A diagnostic endoscopy was performed before the procedure in order to exclude any possible injuries using a double-channel endoscope, Olympus CV 160 (Olympus Medical Systems Corp., Tokyo, Japan), and insufflation with CO₂. A specifically developed esophageal overtube (Apollo Endosurgery, Austin, TX, USA) was used to facilitate the repeated and trauma-free passage of the suturing device and to minimize insufflation gas loss, as it features a balloon at its proximal extremity.

OverStich® is an endoscopic suturing system which is attached to a double-channel endoscope to perform suturing using a curved needle and polypropylene 2-0 thread to a depth of 15 mm (Figure 1). The drive system is attached to the endoscope handle, while the needle is mounted on the distal end of the device. The needle and the suture are grasped by a system that mimics a needle holder and from where it is possible to deploy, place and remove the thread from the suturing system. The stitches can be either continuous or separate after grasping the tissue with the Helix® device (Apollo Endosurgery, Austin, TX, USA), whose function is to drive the tissue into the system and thus allow for full-thickness suturing (Figure 2). At the end of each suture, a knot-closing and cutting system passes through the device’s working channel to complete it (Figure 3).

The first stitch was placed just above the incisura

FIGURE 1 - Overstitch® Endoscopic Suturing Device; Apollo Endosurgery, Austin, TX, USA

FIGURE 2 - A) Needle and thread assembly; B) needle retraction (preparation for suture stitch); C) tissue Helix® device; D) overtube run-through

FIGURE 3 - A) Grasping the tissue with the Helix® device; B) tissue traction into the device; C) stitch run-through; D) preparation for new suture

FIGURE 4 - A) Knot pusher; B) tissue retraction and release at end of plication; C and D) Final aspect
RESULTS

The 56 year-old male patient with a BMI of 35.17 kg/m² had been treated for the previous two years by the institution’s multidisciplinary team and failed clinical/drug treatment for obesity. The patient did not have comorbidities; he was a former smoker and complained of joint pain in the lower limbs. Laboratory and imaging exams were normal, except for an ultrasound image suggesting hepatic steatosis. Previous upper digestive endoscopy was found to be normal and the urease test was negative.

The patient woke up with mild abdominal pain, without nausea or vomiting. A CT scan and contrast X-ray (iodinated contrast) were performed on the day of the procedure, identifying a small pneumoperitoneum and gastric tubulization, but no contrast leakage. The following day a new imaging evaluation was performed with the absence of pneumoperitoneum. Since the patient had no complaints, he was put on a liquid diet without residues and was discharged from the hospital on the second day after surgery.

DISCUSSION

Intraluminal endoscopic suturing was initially developed with the goal of treating GERD. Overstitch™ performs full-thickness suturing, allowing for a serosa to serosa approximation with lasting plication durability. This was evidenced by the presence of pneumoperitoneum after the procedure, which is indicative of gas leakage into the cavity after suturing. The first-in-human case report, the procedure initially lasted 3.48 h, decreasing to 2 h at the end of the series, after technique improvements. In 2013 Abu Dayeh et al. demonstrated technical viability and safety in a series of four cases. Other studies have been published in the literature reporting significant weight loss, even in the medium term.

In a prospective series of 55 patients, six to eight plications were performed in each case, with ≥2 major complications. During radiological evaluation six months after the procedure, it was found that the stomach’s tubular aspect had been preserved. There was a loss of 18.9 kg and 55.3% excess weight.

Lopez-Nava and Galvão Neto et al., in a one-year follow-up study including 25 patients, did not observe major complications, with average procedure time of 80 min (50-120). There was a total weight loss of 18.7% after one year, related to a multidisciplinary follow-up, with statistics demonstrating that the number of visits to a nutritionist and psychologist influenced the results. It was possible to perform an endoscopic evaluation one year after the procedure in half (50%) of the patients and radiological evaluation in 80% of patients, showing that the tubular aspect remained after this period. In only one case was it necessary to perform a new procedure due loss of plication. ESG is durable after one year, with possible repetition of the procedure, if necessary, thus reaching weight loss increments.

In a multicenter evaluation of 242 patients, there was a TBWL of 19.8% after 18 months, with a serious complication rate of 2%—perigastric fluid collection treated with percutaneous drainage and antibiotics, self-limited hemorrhage from splenic laceration, pulmonary embolism, pneumoperitoneum/pneumothorax—without deaths or severe outcomes. OverStitch™ has recently been approved by the agency of the Health Ministry, ANVISA, for use in Brazil. The case described in this report is a pioneer in this country.

The ESG was performed in a total time of 50 min, within the same standard as described in the literature, without bleeding or other complications during the procedure. The patient did not present early complications and continues to be an outpatient attended by a multidisciplinary team.

ESG is a less invasive and cheaper alternative than conventional bariatric surgery, with promising results, especially when performed with multidisciplinary follow-up.

CONCLUSION

The endoscopic sleeve gastroplasty is safe, with acceptable technical viability and reproducibility, with a short procedure time and without early complications.

REFERENCES

1. Abu Dayeh BK, Acosta A, Camilleri M, Mundi MS, Rajan E, Topazian MD, et al. Endoscopic Sleeve Gastropathy Alters Gastric Physiology and Induces Loss of Body Weight in Obese Individuals. Clin Gastroenterol Hepatol. 2015 Dec 31.
2. Abu Dayeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastropathy: a potential endoscopic alternative to sleeve gastrectomy for treatment of obesity. Gastrointest Endosc. 2013 Sep;77(3):530-5.
3. Costa RC, Yamaguchi N, Santo MA, Ricoppo D, Pinto-Junior PE. Outcomes on quality of life, weight loss, and comorbidities after Roux-en-Y gastric bypass. Arq Gastroenterol. 2014 Jul-Sep;51(3):165-70.
4. Kadirukananathan SS, Evans DF, Gong F, Yazaki E, Scott M, Swan CP. Antireflux operations at flexible endoscopy using endoluminal stitching techniques: an experimental study. Gastrointest Endosc. 1996 Aug;44(2):133-43.
5. Kumar N. Endoscopic therapy for weight loss: Gastropasty, duodenal sleeves, intragastric balloons, and aspiration. World J Gastroenterol. 2015 Jul 25;21(27):847-59.
6. Kumar N, Sahdala HNP, Shahril S, Wilson EB, Manceal GN, Zundel N, et al. Endoscopic Sleeve Gastropathy for Obesity: A Multicenter Study of 242 Patients With 18 Months Follow-Up. Gastroenterology. 2014 Apr;146(5):S-572.
7. Lopez-Nava Breviere G, Bautista-Castano I, Fernandez-Corbelle JP, Trell M. Endoscopic sleeve gastropathy (the Apollo method): a new approach to obesity management. Rev Esp Enferm Dig. 2016 Apr;108(4):201-6.
8. Lopez-Nava G, Galvao M, Bautista-Castano, Fernandez-Corbelle JP, Trell M. Endoscopic sleeve gastropathy with 1-year follow-up: factors predictive of success. Endosc Int Open. 2016 Feb;4(2):E222-7.
9. Lopez-Nava G, Galvao MP, da Bautista-Castano I, Jimenez A, De Grado T, Fernandez-Corbelle JP. Endoscopic sleeve gastropasty for the treatment of obesity. Endoscopy. 2015 May;47(5):449-52.
10. Lopez-Nava G, Shariha RZ, Neto MG, Kumta NA, Topazian M, Shukla A. Endoscopic Sleeve Gastropathy for Obesity: A Multicenter Study of 242 Patients With 18 Months Follow-Up. Gastroenterology. 2016 Apr;150(4):S-5-26.
11. Mechanick J, Youdim A, Jones DB, Gavney WT, Hurley DL, McMahon MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Bariatric Surgery. Obesity (Silver Spring). 2013 Mar;21 Suppl 1:S1-27.
12. Ramos A, Galvao Neto M, Galvao M, Evangelista LF, Campos JM, Ferraz A. Laparoscopic greater curvature plication: initial results of an alternative restrictive bariatric procedure. Obes Surg. 2010 Jul;20(7):913-8.
13. Ryo M, Ryan MB, Thompson CC. Current status of endoluminal bariatric procedures for primary and revision indications. Gastrointest Endosc Clin N Am. 2011 Apr;21(2):315-33.
14. Shariha RZ, Kedia P, Shukla A, DeFilippis EM, Gaichhane M, Shukla A, et al. Initial experience with endoscopic sleeve gastropasty: technical success and reproducibility in the bariatric population. Endoscopy. 2015 Feb;47(2):164-6.
15. Swan P, Park PO, Mills T. Bard EndoCinch: the device, the technique, and pre-clinical studies. Gastrointest Endosc Clin N Am. 2003 Jan;13(1):75-88.